Literature DB >> 34050325

Synergistic bactericidal activities of tobramycin with ciprofloxacin and azithromycin against Klebsiella pneumoniae.

Huan Ren1, Jingyi Zhang1, Jingyi Zhou1, Congjuan Xu1, Zheng Fan1, Xiaolei Pan1, Shouyi Li1, Yuying Liang2, Shuiping Chen2, Jun Xu3, Penghua Wang3, Yanhong Zhang4, Guangbo Zhu5, Huimin Liu5, Yongxin Jin1, Fang Bai1, Zhihui Cheng1, Daniel Pletzer6, Weihui Wu7.   

Abstract

Trans-translation is a unique bacterial ribosome rescue system that plays important roles in the tolerance to environmental stresses. It is composed of an ssrA-encoded tmRNA and a protein SmpB. In this study, we examined the role of trans-translation in antibiotic tolerance in Klebsiella pneumoniae and explored whether the inhibition of this mechanism could enhance the bactericidal activities of antibiotics. We found that deletion of the ssrA gene reduced the survival of K. pneumoniae after treatment with kanamycin, tobramycin, azithromycin, and ciprofloxacin, indicating an important role of the trans-translation in bacterial antibiotic tolerance. By using a modified ssrA gene with a 6×His tag we demonstrated that tobramycin suppressed the azithromycin and ciprofloxacin-elicited activation of trans-translation. The results were further confirmed with a trans-translation reporter system that is composed of a normal mCherry gene and a gfp gene without the stop codon. Compared to each individual antibiotic, combination of tobramycin with azithromycin or ciprofloxacin synergistically enhanced the killing activities against planktonic K. pneumoniae cells and improved bacterial clearance in a murine cutaneous abscess infection model. In addition, the combination of tobramycin and ciprofloxacin increased the bactericidal activities against biofilm-associated cells. Overall, our results suggest that the combination of tobramycin with azithromycin or ciprofloxacin is a promising strategy in combating K. pneumoniae infections.
© 2021. The Author(s), under exclusive licence to the Japan Antibiotics Research Association.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34050325     DOI: 10.1038/s41429-021-00427-0

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  5 in total

Review 1.  Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.

Authors:  M Schulz; A Schmoldt
Journal:  Pharmazie       Date:  2003-07       Impact factor: 1.267

2.  Gradual increase in antibiotic concentration affects persistence of Klebsiella pneumoniae.

Authors:  Huan Ren; Xin He; Xiaoli Zou; Guoqing Wang; Shuhua Li; Yanxia Wu
Journal:  J Antimicrob Chemother       Date:  2015-08-25       Impact factor: 5.790

3.  CRISPR-Cas9 and CRISPR-Assisted Cytidine Deaminase Enable Precise and Efficient Genome Editing in Klebsiella pneumoniae.

Authors:  Yu Wang; Shanshan Wang; Weizhong Chen; Liqiang Song; Yifei Zhang; Zhen Shen; Fangyou Yu; Min Li; Quanjiang Ji
Journal:  Appl Environ Microbiol       Date:  2018-11-15       Impact factor: 4.792

4.  A Small-Molecule Inhibitor of trans-Translation Synergistically Interacts with Cathelicidin Antimicrobial Peptides To Impair Survival of Staphylococcus aureus.

Authors:  Yueyang Huang; John N Alumasa; Lauren T Callaghan; R Samuel Baugh; Christopher D Rae; Kenneth C Keiler; Shauna M McGillivray
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

5.  Absence of tmRNA Has a Protective Effect against Fluoroquinolones in Streptococcus pneumoniae.

Authors:  Liliana Brito; Joana Wilton; María J Ferrándiz; Alicia Gómez-Sanz; Adela G de la Campa; Mónica Amblar
Journal:  Front Microbiol       Date:  2017-01-10       Impact factor: 5.640

  5 in total
  1 in total

1.  Antibacterial Efficacy of Liposomal Formulations Containing Tobramycin and N-Acetylcysteine against Tobramycin-Resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii.

Authors:  Reem E Alarfaj; Manal M Alkhulaifi; Ahmed J Al-Fahad; Shokran Aljihani; Alaa Eldeen B Yassin; Majed F Alghoribi; Majed A Halwani
Journal:  Pharmaceutics       Date:  2022-01-05       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.